Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:38 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 5,323 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Continuous Dose Clear all
Completed Early Phase 1 Interventional

Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients

NCT04145323
View directory record Official record
Conditions
Breast Cancer, Necrosis
Interventions
ICG microangiography
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 3 Interventional Results available

VA Augmentation and Switching Treatments for Improving Depression Outcomes

NCT01421342
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Switching: Bupropion-SR, Augmenting: Antidepressant + Bupropion-SR, Augmenting: Antidepressant + Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
35
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Nov 3, 2026, 6:38 PM EST
Terminated Phase 2 Interventional Results available

Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer

NCT00402883
View directory record Official record
Conditions
Lung Cancer
Interventions
Bevacizumab, Pemetrexed, Radiotherapy, Folic Acid, vitamin B12, carboplatin
Drug · Procedure · Other
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
7
States / cities
Gainesville, Florida • Lakeland, Florida • Marietta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Nov 3, 2026, 6:38 PM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

Cyclic Versus Daily Teriparatide on Bone Mass

NCT00668941
View directory record Official record
Conditions
Osteoporosis
Interventions
Teriparatide, Alendronate, Calcium, Vitamin D3
Drug · Dietary Supplement
Lead sponsor
Helen Hayes Hospital
Other
Eligibility
45 Years to 85 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2017
U.S. locations
1
States / cities
West Haverstraw, New York
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 2 Interventional Results available

Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients

NCT00428922
View directory record Official record
Conditions
Breast Cancer
Interventions
Trastuzumab, Bevacizumab, Docetaxel
Drug
Lead sponsor
Bhuvaneswari Ramaswamy
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
3
States / cities
Cleveland, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 3 Interventional Results available

A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium

NCT00865202
View directory record Official record
Conditions
Post-operative Delirium
Interventions
L-tryptophan supplementation, placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Alpelisib in Healthy Volunteers

NCT05733455
View directory record Official record
Conditions
Insulin Resistance, Hyperinsulinemia, Dyslipidemias
Interventions
Alpelisib 150 mg [Piqray], 2 overencapsulated tablets (total: 300 mg), Placebo (microcrystalline cellulose), 2 capsules, FreeStyle Libre Pro, Oral glucose tolerance test (OGTT) with Trutol glucose beverage, BOOST Plus nutritional beverage
Drug · Device · Diagnostic Test + 1 more
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Nov 3, 2026, 6:38 PM EST
Recruiting Phase 3 Interventional

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

NCT06012240
View directory record Official record
Conditions
Alopecia Areata
Interventions
Upadacitinib, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 63 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
78
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 3 Interventional Results available

A Study of Soticlestat as an Add-on Therapy in Children and Young Adults With Dravet Syndrome

NCT04940624
View directory record Official record
Conditions
Dravet Syndrome (DS)
Interventions
Soticlestat, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years to 21 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 4 Interventional Results available

Extended Release Naltrexone for Opioid-Dependent Youth

NCT01843023
View directory record Official record
Conditions
Drug Dependence
Interventions
Extended Release Naltrexone, Psychosocial Treatment, Buprenorphine
Drug · Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
15 Years to 21 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Nov 3, 2026, 6:38 PM EST
Terminated Phase 1 Interventional Results available

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

NCT04060862
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Placebo, Palbociclib, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1Phase 2 Interventional Results available

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

NCT00473746
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, prednisone/prednisolone or dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 2 Interventional Results available

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

NCT00313560
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
erlotinib hydrochloride
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 3, 2026, 6:38 PM EST
Withdrawn Phase 4 Interventional

Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury

NCT03095222
View directory record Official record
Conditions
Pain
Interventions
Ketamine, Opioids
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Nov 3, 2026, 6:38 PM EST
Terminated Phase 2 Interventional Results available

A Study Designed to Evaluate ODSH in Subjects With Exacerbations of COPD

NCT00457951
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Open-Label, Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride, ODSH
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Orange, California • Marietta, Georgia • Shreveport, Louisiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Nov 3, 2026, 6:38 PM EST
Not listed Phase 4 Interventional

Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER

NCT04118829
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Perampanel
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2021 · Synced Nov 3, 2026, 6:38 PM EST
Recruiting Early Phase 1 Interventional

Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder

NCT06582888
View directory record Official record
Conditions
Nicotine Addiction, Craving
Interventions
Varenicline Tartrate, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)

NCT06101329
View directory record Official record
Conditions
Pre-Exposure Prophylaxis of HIV Infection
Interventions
Lenacapavir Tablet, Lenacapavir Injection, Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
11
States / cities
Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Not listed Phase 1Phase 2 Interventional

Venetoclax and Lintuzumab-Ac225 in AML Patients

NCT03867682
View directory record Official record
Conditions
Acute Myeloid Leukemia, Relapsed Adult AML
Interventions
Lintuzumab-Ac225, Venetoclax, Spironolactone
Biological · Drug
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Louisville, Kentucky • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 2 Interventional Results available

Treatment and Natural History Study of Lymphomatoid Granulomatosis

NCT00001379
View directory record Official record
Conditions
Lymphomatoid Granulomatosis, Granulomatosis, Lymphomatoid, Non-Hodgkins Lymphoma, Lymphoproliferative Disorder
Interventions
Interferon, Rituxan and EPOCH, Tumor biopsy, Bone marrow biopsy, Bone marrow aspirate, Lumber puncture, CT, Brain MRI, Echocardiogram, FDG-PET
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Nov 3, 2026, 6:38 PM EST
Withdrawn Phase 2 Interventional

BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases

NCT04183062
View directory record Official record
Conditions
Osteosarcoma Metastatic, Ewing's Sarcoma Metastatic
Interventions
Chemotherapy (gemcitabine & docetaxel) plus BIO-11006
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
5 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Nov 3, 2026, 6:38 PM EST
Completed Phase 1 Interventional

Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

NCT00093483
View directory record Official record
Conditions
Leukemia
Interventions
filgrastim, arsenic trioxide, cytarabine, idarubicin
Biological · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years to 59 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2014 · Synced Nov 3, 2026, 6:38 PM EST
Recruiting Phase 2 Interventional

ctHPVDNA Response-Adapted Chemoradiation +/- Retifanlimab Treatment in Locally-Advanced Anal Cancer

NCT07425054
View directory record Official record
Conditions
Anal Cancer, HPV-Related Carcinoma, Squamous Cell Carcinoma of the Anus
Interventions
HPV ctDNA Response based radiation, Chemotherapy, Retifanlimab
Radiation · Drug
Lead sponsor
Jennifer Dorth
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Nov 3, 2026, 6:38 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT04743505
View directory record Official record
Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
APL-101, Osimertinib
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Nov 3, 2026, 6:38 PM EST